Crandell Keith 的 Form 4 申報
Neumora Therapeutics, Inc.（NMRA），2023/11/7 申報
- 申報編號
- 0001062993-23-020279
- 申報時間
- 2023/11/7 18:59 ET
- 交易日
- 2023/11/3-11/7
- 申報延遲
- 4 天
- 10b5-1 計畫
- 沒有勾選
這份申報列了 3 筆非衍生性交易。公開市場買進合計 $110.0 萬。交易後 4 天申報。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Crandell KeithCIK 0001219039 | 持股 10% 以上大股東 |
| Nelsen RobertCIK 0001219042 | 持股 10% 以上大股東 |
| Gillis StevenCIK 0001229592 | 持股 10% 以上大股東 |
| ARCH Venture Fund XII, L.P.CIK 0001906837 | 持股 10% 以上大股東 |
| ARCH Venture Partners XII, LLCCIK 0001979548 | 持股 10% 以上大股東 |
| ARCH Venture Partners XII, L.P.CIK 0001979765 | 持股 10% 以上大股東 |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F1
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.08 to $11.82, inclusive. The reporting person undertakes to provide to NMRA, any security holder of NMRA, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form 4.
表 I 有 1 筆交易的價格引用這則附註。
- F2
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.34 to $11.99, inclusive.
表 I 有 1 筆交易的價格引用這則附註。
- F3
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.34 to $11.67, inclusive.
表 I 有 1 筆交易的價格引用這則附註。
備註
This Form 4 is filed jointly by ARCH XII, AVP XII LP, AVP XII LLC, Robert Nelsen, Steven Gillis, Keith Crandell (collectively, the "Reporting Persons"). Kristina Burow has direct ownership of common stock and is filing her own Form 4 separately.